AstraZeneca asks FDA to delay ANDAs for Crestor generics

AstraZeneca has filed a citizen petition to the US Food and Drug Administration (FDA) requesting it to wait until 2023 before approving generic versions of Crestor (rosuvastatin calcium), a cholesterol treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Jones Day adds in-house biologics specialist to Boston office

20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.

Americas

Kirkland & Ellis subject of alleged conflict in trade secrets clash

19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".

Americas

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

19 May 2026 The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza.

More features

Healthcare leads sweeping AI partnership in Singapore

Jones Day adds in-house biologics specialist to Boston office

Kirkland & Ellis subject of alleged conflict in trade secrets clash

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

Orrick lands five-member M&A team in Paris

AbbVie’s trade secret suit against a Chinese rival gets green light

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

Blank Rome adds to growing team with patent agent from MBHB

AstraZeneca asks FDA to delay ANDAs for Crestor generics

More on this story

Editor's picks

Editor's picks

More features